| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Adrienne Stevens | Q107974680 |
| P2093 | author name string | Adam E Haynes | |
| Ralph M Meyer | |||
| Matthew C Cheung | |||
| Kevin R Imrie | |||
| Members of the Hematology, Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 161-176 | |
| P577 | publication date | 2007-01-22 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario | |
| P478 | volume | 33 |
| Q37901704 | Antiepileptic drug therapy: does mechanism of action matter? |
| Q35547392 | Cluster-based comparison of the peptide mass fingerprint obtained by MALDI-TOF mass spectrometry. A case study: long-term stability of rituximab |
| Q38988648 | Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface. |
| Q34763541 | Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews. |
| Q37940987 | Hepatitis C Virus-related Mixed Cryoglobulinemia: Pathogenesis, Clinica Manifestations, and New Therapies |
| Q38030533 | Hepatitis C virus infection and mixed cryoglobulinemia |
| Q34415869 | Induction of interleukin-6 production by rituximab in human B cells |
| Q24240781 | Interferon-alpha for maintenance of follicular lymphoma |
| Q38066195 | Mechanisms of action of CD20 antibodies |
| Q37819809 | Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier |
| Q33846734 | NHL (diffuse large B-cell lymphoma). |
| Q38132359 | Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance |
| Q57048060 | Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study |
| Q34757945 | Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence? |
| Q46456370 | Quality of life research: adding an important dimension to the evaluation of therapeutic outcomes |
| Q54768263 | Quantification of an intact monoclonal antibody, rituximab, by (RP)HPLC/DAD in compliance with ICH guidelines. |
| Q24241273 | Rituximab as maintenance therapy for patients with follicular lymphoma |
| Q37948748 | Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials |
| Q37391070 | Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials |
| Q36326867 | Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis |
| Q34750560 | Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. |
| Q47320329 | The Effects of Light-Accelerated Degradation on the Aggregation of Marketed Therapeutic Monoclonal Antibodies Evaluated by Size-Exclusion Chromatography With Diode Array Detection |
Search more.